Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Valion Bio, Inc. Common Stock (NASDAQ:VBIO) to a hold rating in a research report report published on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Valion Bio, Inc. Common Stock currently has an average rating of “Sell”.

Valion Bio, Inc. Common Stock Price Performance

Valion Bio, Inc. Common Stock stock opened at $2.77 on Friday. The business’s 50-day simple moving average is $7.41 and its two-hundred day simple moving average is $16.85. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.86 and a current ratio of 1.11. The company has a market cap of $2.47 million, a PE ratio of -0.43 and a beta of 1.79. Valion Bio, Inc. Common Stock has a fifty-two week low of $2.70 and a fifty-two week high of $80.19.

About Valion Bio, Inc. Common Stock

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.